ReviewBlood2019
How I treat refractory chronic graft-versus-host disease.
Review in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.Transplantation and cellular therapy · 2024Guideline
- Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.Current oncology (Toronto, Ont.) · 2024Guideline
- Pooled it
- A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.Blood advances · 2022Trial
- Trial
- Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.Cell transplantationTrial
- Pediatric diamond-blackfan anemia after hematopoietic stem cell transplantation complicated by bronchiolitis obliterans and air-leak syndrome leading to lung transplantation: a case report with multimodal follow-up.Frontiers in immunology · 2026Article
- Chronic Graft-versus-host Disease, Part 2: Clinical Success and Roadmap to the Future.Transplantation · 2025Review
- Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis.Blood advances · 2025Article
- MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness.Frontiers in immunology · 2025Article
- ROCK 2 inhibition with belumosudil for the treatment of chronic graft-versus-host disease: a narrative review.Therapeutic advances in hematology · 2025Review
- Clinical Outcomes Among Patients With Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Literature Review.Journal of blood medicine · 2025Review
- Establishing a Graft-Versus-Host Disease (GVHD)-Focused Multidisciplinary Telehealth Clinic.Transplantation and cellular therapy · 2024Article
- Review
- Disability Associated with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of a Cross-Sectional US Patient Survey.Oncology and therapy · 2024Article
- International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.Bone marrow transplantation · 2024Review
- How does ocular graft-versus-host disease fit under the dry eye umbrella? A review.Clinical & experimental ophthalmology · 2024Review
- Chronic graft-versus-host disease. Part II: Disease activity grading and therapeutic management.Journal of the American Academy of Dermatology · 2024Review
- More evidence for low-dose IL-2 for chronic GVHD in children.Blood advances · 2023Article
- A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore.Cost effectiveness and resource allocation : C/E · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Approximately 35% to 50% of patients otherwise cured of hematologic malignancies after allogeneic hematopoietic stem cell transplantation will develop the pleomorphic autoimmune-like syndrome known as chronic graft-versus-host disease (cGVHD). Since in 2005, National Institutes of Health (NIH) consensus panels have proposed definitions and classifications of disease to standardize treatment trials. Recently, the first agent was approved by the US Food and Drug Administration for steroid-refractory cGVHD. Despite these advances, most individuals do not achieve durable resolution of disease activity with initial treatment. Moreover, standardized recommendations on how to best implement existing and novel immunomodulatory agents and taper salvage agents are often lacking. Given the potential life-threatening nature of cGVHD, we employ in our practice patient assessment templates at each clinic visit to elucidate known prognostic indicators and red flags. We find NIH scoring templates practical for ongoing assessments of these complex patient cases and determination of when changes in immunosuppressive therapy are warranted. Patients not eligible or suitable for clinical trials have systemic and organ-directed adjunctive treatments crafted in a multidisciplinary clinic. Herein, we review these treatment options and offer a management and monitoring scaffold for representative patients with cGVHD not responding to initial therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.